Evernorth's Accredo arm will make a Humira biosimilar available to patients with no out-of-pocket costs, the company ...

Hello and welcome to the first quarter 20204 Teva Pharmaceuticals Industries Limited earnings conference call. My name is ...

In an important step toward driving long-term affordability and access to treatments for chronic and complex conditions, Evernorth Health Services announced that it will have a Humira® biosimilar ...

For many employers, unions, municipalities and other health plan sponsors that choose to work with Accredo as part of their specialty pharmacy network offering, this represents an opportunity for ...

For many employers, unions, municipalities and other health plan sponsors that choose to work with Accredo as part of their specialty pharmacy network offering, this represents an opportunity for ...

For many employers, unions, municipalities and other health plan sponsors that choose to work with Accredo as part of their specialty pharmacy network offering, this represents an opportunity for ...

Cigna plans to make close copies of AbbVie's blockbuster arthritis drug Humira available with no out-of-pocket payment to ...

Evernorth Health Services' initiative to offer Humira biosimilar with $0 out-of-pocket costs for patients. Save an average of ...

Cigna reported a $300 million first quarter loss as the company grapples with the loss in value of its investment in ...

Moreover, the product will be available to patients at Accredo, which is the PBM’s specialty pharmacy. What CVS Caremark is ...

AbbVie (ABBV) shares were down 6% in the wake of its Q1 earnings report and news that Cigna (CI) plans to offer a Humira ...

Evernorth Health Services will offer Humira biosimilar products with no out-of-pocket cost through its Accredo specialty ...